Expert Review of Anticancer Therapy最新文献_第8页

The discordance of biomarkers in primary tumour and synchronous axillary lymph node metastasis of the breast cancer, and its clinical significance in patients undergoing neoadjuvant therapy. 乳腺癌原发肿瘤与同步腋窝淋巴结转移生物标志物的不一致性及其在新辅助治疗患者中的临床意义

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-10 DOI: 10.1080/14737140.2025.2464199

Ali Kaan Sanal, Umit Turan, Ahmet Yugruk, Zeynel Abidin Taş, Oktay Irkorucu, Omer Taskin

{"title":"The discordance of biomarkers in primary tumour and synchronous axillary lymph node metastasis of the breast cancer, and its clinical significance in patients undergoing neoadjuvant therapy.","authors":"Ali Kaan Sanal, Umit Turan, Ahmet Yugruk, Zeynel Abidin Taş, Oktay Irkorucu, Omer Taskin","doi":"10.1080/14737140.2025.2464199","DOIUrl":"10.1080/14737140.2025.2464199","url":null,"abstract":"Background: This study explores the disparity in ER, PR, HER-2, and Ki-67 status between primary breast tumors (PBT) and axillary lymph node metastasis (ALNM) at initial admission in patients undergoing neoadjuvant chemotherapy (NAC).Research design and methods: Demographic-clinicopathological characteristics and histopathological response to NAC in both PBT and ALNM were recorded. Immunohistochemical analysis of ER, PR, HER-2, and Ki67 was performed separately in PBT and ALNM, with discordance rates compared. The disparity in biomarkers was assessed in relation to the histopathological response to NAC in both PBT and ALNM.Results: In 96 female patients, discordance rates between PBT and ALNM were 16.67% for ER, 16.67% for PR, 20.83% for HER-2, and 15.63% for Ki-67. Statistically significant differences in ER and PR discordance between PBT and ALNM were observed. Additionally, a significant difference in histopathological response to NAC was noted based on ER discordance.Conclusion: Precise assessment of ER and HER-2 status in axillary lymph node biopsy specimens is crucial in breast cancer patients with ALNM, potentially optimizing systemic and surgical treatment selection.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review. 少转移性和少进展性肾细胞癌的治疗：最新综述。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-10 DOI: 10.1080/14737140.2025.2464929

Giulia Claire Giudice, Michele Maffezzoli, Irene Testi, Alessandro Acunzo, Virginia Agnetti, Pietro Tuttobene, Maddalena Donini, Francesco Massari, Veronica Mollica, Alessandro Rizzo, Sebastiano Buti

{"title":"Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review.","authors":"Giulia Claire Giudice, Michele Maffezzoli, Irene Testi, Alessandro Acunzo, Virginia Agnetti, Pietro Tuttobene, Maddalena Donini, Francesco Massari, Veronica Mollica, Alessandro Rizzo, Sebastiano Buti","doi":"10.1080/14737140.2025.2464929","DOIUrl":"https://doi.org/10.1080/14737140.2025.2464929","url":null,"abstract":"Introduction: metastasis-directed treatment (MDT) is progressively expanding its scope in the treatment of metastatic renal cell carcinoma (mRCC), finding application both in cases of oligometastatic disease, whether synchronous or metachronous, and in oligo-progression during systemic therapy (ST). This updated narrative review incorporates recent advancements in managing oligometastatic and oligo-progressive RCC. A PubMed literature search using keywords related to mRCC and its treatments was made. Observational studies, clinical trials, and reviews were analyzed, selecting the most relevant articles based on evidence strength.Areas covered: we analyzed the current role of surgery, both on the primary than on metastatic sites, and the recent advantages in both radiotherapy, ST and focal therapies. Lastly, we focused on single metastatic sites of interest.Expert opinion: nowadays personalized tailored treatments are the key, integrating multimodal approaches like metastasectomy, radiotherapy, and ST. While the role of cytoreductive nephrectomy remains debated, metastasectomy and radiotherapy demonstrates potential in managing both oligometastatic and oligo-progressive disease, either alone or in synergy with ST, though more robust evidence is needed. Future research should focus on identifying biomarkers for treatment selection, optimizing therapy timing, and refining patient stratification to enhance outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nomograms for predicting overall and cancer-specific survival among patients with prostatic ductal adenocarcinoma: a population-base study. 预测前列腺导管腺癌患者总体和癌症特异性生存的nomogram：一项基于人群的研究。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-10 DOI: 10.1080/14737140.2025.2464926

Zhan Zhao, QianSan Zhu

{"title":"Nomograms for predicting overall and cancer-specific survival among patients with prostatic ductal adenocarcinoma: a population-base study.","authors":"Zhan Zhao, QianSan Zhu","doi":"10.1080/14737140.2025.2464926","DOIUrl":"10.1080/14737140.2025.2464926","url":null,"abstract":"Background: Prostatic ductal adenocarcinoma (PDA) is a rare malignant tumor, and research on its clinical features and prognosis is scarce. This study aims to develop prognostic nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) in patients with PDA.Research design and methods: Among the 1,049 identified patients, an 8:2 random division yielded development and validation cohorts. Univariate and multivariate Cox analyses were performed to identify independent prognostic factors, which were then incorporated into nomograms predicting 1-, 3-, and 5-year OS and CSS for patients with PDA. The prognostic nomograms were evaluated using Concordance index (C-index) and receiver operating characteristic (ROC) curve, with internal validation performed through Decision Curve Analysis (DCA).Results: Independent prognostic factors, including age, marital status, lymph node status, distant metastasis, surgery method, chemotherapy, and Gleason score, were incorporated into the developed nomograms. The results of training (C-index: OS = 0.74, CSS = 0.69; AUC value: OS = 0.822-0.892, CSS = 0.836-0.873) and internal validation (C-index: OS = 0.78, CSS = 0.77) indicated our nomograms had good performance The clinical decision curve indicated that the nomogram had a good clinical net benefit.Conclusions: This study successfully established and validated prognostic nomograms tailored for PDA patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.9,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary management of advanced gastric and gastroesophageal adenocarcinomas. 晚期胃及胃食管腺癌的当代治疗。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-08 DOI: 10.1080/14737140.2025.2463493

Jane E Rogers, Jaffer A Ajani

{"title":"Contemporary management of advanced gastric and gastroesophageal adenocarcinomas.","authors":"Jane E Rogers, Jaffer A Ajani","doi":"10.1080/14737140.2025.2463493","DOIUrl":"10.1080/14737140.2025.2463493","url":null,"abstract":"Introduction: Gastric and gastroesophageal adenocarcinomas (GEACs) continue to carry a poor prognosis in most patients. New and exciting therapies have entered the treatment landscape in recent years. Prior to these recent approvals, treatment advances had been limited.Areas covered: Important treatment decision biomarkers for metastatic GEAC are microsatellite instability-high/deficient mismatch repair, human epidermal growth factor receptor-2, programmed-death ligand 1, and claudin 18.2 expression among others (such as Epstein Barr Virus (EBV) and agnostic biomarkers). Results of these biomarkers drive therapy decisions. Second-line treatment in most cases is less biomarker driven and needs further progress.Expert opinion: Studies of molecular subsets in GEAC has led to the understanding that these are heterogenous diseases that need to be treated differently. Other biomarkers with targeted therapies are being studied including fibroblast growth factor receptor, trophoblast cell surface antigen-2, and epidermal growth factor receptor. Additionally, epidemiological distinctions are starting to drive therapy such as in EBV in GAC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.9,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angiotensin system inhibitors improve survival in patients undergoing pancreatic cancer resection: a meta-analysis of real-world evidence. 血管紧张素系统抑制剂提高胰腺癌切除术患者的生存率：现实世界证据的荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-07 DOI: 10.1080/14737140.2025.2464208

Yuxuan Lin, Yonghe Liao, Jinhai Shen

{"title":"Angiotensin system inhibitors improve survival in patients undergoing pancreatic cancer resection: a meta-analysis of real-world evidence.","authors":"Yuxuan Lin, Yonghe Liao, Jinhai Shen","doi":"10.1080/14737140.2025.2464208","DOIUrl":"10.1080/14737140.2025.2464208","url":null,"abstract":"Background: The role of angiotensin system inhibitors (ASIs) in modifying the prognosis for patients undergoing pancreatic cancer resection is not yet definitively established. This meta-analysis endeavors to consolidate existing real-world data to provide a robust, evidence-based assessment of their impact on clinical outcomes.Methods: A meticulous search strategy was devised and executed across PubMed, Embase, and Web of Science databases to retrieve all relevant studies evaluating the prognostic impact of ASIs in patients who have undergone resection for pancreatic cancer. Studies comparing survival outcomes between ASI users and non-users were included in the meta-analysis. Publication bias was assessed using funnel plotand Egger's test. Sensitivity analysis employing the leave-one-out approach was conducted to ensure the robustness and reliability of the pooled estimate.Results: Seven studies encompassing 8,549 patients were analyzed. The utilization of ASIs was significantly associated with improved overall survival (HR: 0.78; 95%CI: 0.68-0.89) in patients undergoing pancreatic cancer resection. Sensitivity analysis further validated the consistency and stability of the pooled result.Conclusion: Current clinical evidence suggests that ASIs are associated with improved prognosis in patients who have undergone pancreatic cancer resection. These findings highlight the potential of ASIs as a beneficial adjunctive therapy in the management of resected pancreatic cancer, warranting their consideration in clinical management protocols.Registration: PROSPERO (identifier: CRD42024580624).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence. 肾素-血管紧张素系统抑制剂对卵巢癌患者预后的影响：真实世界证据的荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-06 DOI: 10.1080/14737140.2025.2463486

Pian Wang, Xinmiao Zhang, Jinhai Shen

{"title":"Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence.","authors":"Pian Wang, Xinmiao Zhang, Jinhai Shen","doi":"10.1080/14737140.2025.2463486","DOIUrl":"10.1080/14737140.2025.2463486","url":null,"abstract":"Background: The prognostic impact of renin-angiotensin system inhibitors (RASIs) on ovarian cancer (OC) remains indeterminate. This meta-analysis aims to consolidate real-world data to provide a comprehensive, evidence-based assessment of the association between RASIs use and clinical outcomes in OC patients.Methods: A meticulous search strategy was devised and executed across PubMed, Scopus, and Embase databases to retrieve all relevant studies evaluating the prognostic impact of RASIs in patients with OC. Studies comparing survival outcomes between RASIs users and non-users were included in the meta-analysis.Results: A total of six studies, encompassing 11 cohorts and 14,634 patients, were included in the meta-analysis. RASIs use was found to be significantly correlated with enhanced survival (HR: 0.82; 95%CI: 0.72-0.92) in the OC patient population. Subgroup analysis showed that ACEIs use (HR: 0.83, 95% CI: 0.78-0.89) and post-diagnostic RASIs use (HR: 0.77, 95% CI: 0.66-0.90) significantly improved overall survival.Conclusion: This meta-analysis provides evidence that RASIs are associated with improved prognosis in OC patients. These findings suggest that RASIs may have potential as an adjunctive therapy in the management of OC, warranting further investigation and consideration in clinical management protocols.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anticancer properties of histone deacetylase inhibitors - what is their potential? 组蛋白去乙酰化酶抑制剂的抗癌特性-它们的潜力是什么？

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-01 Epub Date: 2025-01-16 DOI: 10.1080/14737140.2025.2452338

Kajetan Kiełbowski, Agata Szwedkowicz, Paulina Plewa, Estera Bakinowska, Rafał Becht, Andrzej Pawlik

{"title":"Anticancer properties of histone deacetylase inhibitors - what is their potential?","authors":"Kajetan Kiełbowski, Agata Szwedkowicz, Paulina Plewa, Estera Bakinowska, Rafał Becht, Andrzej Pawlik","doi":"10.1080/14737140.2025.2452338","DOIUrl":"10.1080/14737140.2025.2452338","url":null,"abstract":"Introduction: Histone modifications are crucial epigenetic mechanisms for regulating gene expression. Histone acetyltransferases and deacetylases (HDACs) catalyze histone acetylation, a process that mediates transcription. Over recent decades, studies have demonstrated that targeting histone acetylation can be effective in cancer treatment, leading to the development and approval of several HDAC inhibitors.Areas covered: A comprehensive literature review was conducted using the PubMed database to identify studies evaluating the anticancer efficacy of approved and novel HDAC inhibitors.Expert opinion: Accumulating evidence highlights the promising benefits of combining HDAC inhibitors with other anticancer agents. Additionally, HDAC-targeting therapeutics could enhance the sensitivity of cancer cells to chemotherapeutics or targeted tyrosine kinase inhibitors, thereby improving overall treatment outcomes. Future clinical studies must focus on optimizing combination therapies to ensure efficacy while maintaining manageable safety profiles.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"105-120"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer? 重新评估前景：原发性肿瘤手术真的是生存的关键还是仅仅是对新发IV期乳腺癌的误解？

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-01 Epub Date: 2025-01-17 DOI: 10.1080/14737140.2025.2454998

Gianluca Franceschini

引用次数: 0

Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different PD-L1 expression levels. 免疫检查点抑制剂加紫杉烷化疗治疗晚期/转移性非小细胞肺癌：不同PD-L1表达水平的系统回顾和荟萃分析

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-01 Epub Date: 2025-02-03 DOI: 10.1080/14737140.2025.2460537

Aws Khalid Abushanab, Mus'ab Theeb Mustafa, Mahmoud Taysir Mousa, Renad Fawwaz Albanawi, Razan Mohammad Alkhalaileh, Ghaith Nahar Alqudah, Razan Feras Abu Zaina, Zaina Ammar Abu Sitta, Issa Mohammad Almasri, Dua Abuquteish

{"title":"Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different PD-L1 expression levels.","authors":"Aws Khalid Abushanab, Mus'ab Theeb Mustafa, Mahmoud Taysir Mousa, Renad Fawwaz Albanawi, Razan Mohammad Alkhalaileh, Ghaith Nahar Alqudah, Razan Feras Abu Zaina, Zaina Ammar Abu Sitta, Issa Mohammad Almasri, Dua Abuquteish","doi":"10.1080/14737140.2025.2460537","DOIUrl":"10.1080/14737140.2025.2460537","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) are currently the primary approach for managing NSCLC. However, numerous combination therapies are currently under investigation. Our goal is to investigate the overall efficacy and safety of ICIs and taxane-based chemotherapy.Methods: We conducted a systematic review and meta-analysis, searching web databases for relevant literature. We limited our eligibility to phase II/III randomized clinical trials involving advanced/metastatic NSCLC patients.Results: We performed a meta-analysis encompassing nineteen studies derived from sixteen RCTs. For patients with sq-NSCLC PD-L1 ≥ 50%, using ICIs plus taxane significantly improve PFS and OS with HR of 0.58 (95% CI, 0.45-0.74, p < 0.0001) and 0.41 (95% CI, 0.33-0.50, p < 0.00001), respectively. For patients with non-sq NSCLC PD-L1 1-49%, the analysis revealed significant improvement of OS and PFS with HR of 0.64 (95% CI, 0.47-0.88, p = 0.005) and 0.62 (95% CI, 0.47-0.81, p = 0.0004), respectively. For TRAEs of all grades, ICIs plus taxane resulted with no significant difference compared to control group with risk ratio (RR) 1.00 (95% CI 0.99-1.02).Conclusion: The analysis revealed significant improvement in efficacy of ICIs with taxane in advanced/metastatic NSCLC patients compared with ICI/taxane monotherapy.Registration: PROSPERO (CRD42023447532).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"167-179"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in immunotherapy for hepatocellular carcinoma. 肝细胞癌免疫治疗的进展。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-02-01 Epub Date: 2025-02-06 DOI: 10.1080/14737140.2025.2461631

Sara Ascari, Rusi Chen, Caterina Vivaldi, Bernardo Stefanini, Andrea De Sinno, Andrea Dalbeni, Piera Federico, Francesco Tovoli

{"title":"Advancements in immunotherapy for hepatocellular carcinoma.","authors":"Sara Ascari, Rusi Chen, Caterina Vivaldi, Bernardo Stefanini, Andrea De Sinno, Andrea Dalbeni, Piera Federico, Francesco Tovoli","doi":"10.1080/14737140.2025.2461631","DOIUrl":"10.1080/14737140.2025.2461631","url":null,"abstract":"Introduction: The advent of immune-based combinations, primarily leveraging immune checkpoint inhibitors, has revolutionized the therapeutic landscape of hepatocellular carcinoma (HCC). The current scenario features multiple therapies that have shown superiority over tyrosine kinase inhibitors; however, the absence of direct comparisons and validated prognostic biomarkers complicates therapeutic decision-making. Additionally, a significant proportion of patients still exhibit primary or secondary resistance to existing immunotherapies, underscoring the ongoing need for novel therapeutic strategies.Areas covered: This narrative review discusses current strategies aimed at improving the efficacy of immunotherapy for HCC, focusing on the following aspects: available therapeutic options, identification of prognostic biomarkers, approaches to overcoming resistance (including the development of neoantigen vaccines), and the exploration of adjuvant and neoadjuvant strategies.Expert opinion: The future of systemic therapies for HCC is likely to be driven by advancements in immunotherapy. Key areas of exploration for the coming years include the discovery of novel checkpoint inhibitors or complementary agents to enhance tumor response when combined with existing treatments, a shift toward neoadjuvant/perioperative trials instead of traditional adjuvant approaches, and the development of personalized neoantigen vaccines.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"151-165"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0